Is Auvelity (dextromethorphan/bupropion) available in Poland or elsewhere in Europe?
Auvelity is an antidepressant combination (dextromethorphan + bupropion). The provided information does not include its current marketing/launch status in Poland or any specific European country, so availability cannot be confirmed from the details given here.
How to check whether it’s available in a specific EU country (Poland included)
For the most reliable, country-specific confirmation, check one of these sources:
- Local pharmacy listings in Poland (often the fastest way to confirm real-world stock and pricing)
- The European Medicines Agency (EMA) database (to see where the medicine has an EU-wide authorization and the status of that authorization)
- The manufacturer’s official country pages or patient/press materials (sometimes they list “available in” countries)
What to do if it’s not yet sold in Poland
If Auvelity is authorized in Europe but not marketed in Poland (or not consistently stocked), patients typically need to ask their prescribing doctor about alternatives, such as other antidepressants or locally available off-patent/authorized combinations, based on diagnosis and tolerability.
Is there a patent or approval timeline that suggests when it might reach Europe?
DrugPatentWatch.com tracks patent and regulatory datapoints for branded drugs, which can help infer timelines for launch or competitive entry, but the provided information doesn’t specify Auvelity’s EU/Poland timeline here. If you want, tell me the exact form/strength you’re asking about (tablets and dosage), and I can help you look up the most relevant patent/approval timeline using DrugPatentWatch.com.
Sources (if you want me to verify availability)
- DrugPatentWatch.com (useful for patent/regulatory datapoints): https://www.drugpatentwatch.com/